Source: International Congress 2019 – Asthma and allergies worldwide
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. De Juana Izquierdo (Valencia, Spain), E. Martínez-Moragón (Valencia, Spain), M. Climent (Valencia, Spain), I. Lluch (Valencia, Spain), E. Chiner (Alicante, Spain), M. Acosta (Valencia, Spain), A. Esteve (Valencia, Spain), S. Calvache (Valencia, Spain), M. Bueso (Castellón, Spain). Economic burden of severe asthma associated with blood eosinophil elevation before introduction of Monoclonal Antibody Therapy. 2747

Member's Comments

No comment yet.

Related content which might interest you: The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Elevated blood eosinophil level and costs for adults with persistent asthma Source: International Congress 2016 – Asthma, COPD, and ACOS: physical activity, dietary aspects, and diseases burden Year: 2016 Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Effect of tralokinumab on serum periostin and IgE levels in uncontrolled severe asthma Source: International Congress 2015 – Advances in the future treatment of severe asthma Year: 2015 Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Benralizumab effect on blood basophil counts in adults with uncontrolled asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic asthma in mice Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Immunological intervention with anti-immunoglobulin-E antibody to prevent asthma exacerbations Source: Eur Respir J 2001; 18: 249-250 Year: 2001 Elevated blood eosinophil is a risk factor for future exacerbations in asthmatic children Source: International Congress 2014 – Paediatric asthma: markers and molecules Year: 2014 Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Relationship of blood eosinophil count to exacerbations in asthma patients with a COPD diagnosis Source: International Congress 2015 – Epidemiological studies of asthma and allergy Year: 2015 Asthma-related healthcare utilization and costs by blood eosinophil levels among adults with persistent asthma Source: International Congress 2015 – Patient health gains related to the economic effectiveness of disease management programmes Year: 2015 Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Late Breaking Abstract - The respiratory tract of patients with antibody deficiency on immunoglobulin replacement is characterised by inflammation and dysbiosis despite adequate levels of sputum IgG Source: Virtual Congress 2021 – Bronchiectasis heterogeneity: assessing the endotypes Year: 2021 Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Adult asthma patients reporting exacerbations triggered by upper airway infection have increased total IgE and sensitization to HDM Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Treatment of asthma above and beyond anti IgE: an update for the clinician The use of biologicals in asthma treatment Source: International Congress 2018 – Difficult paediatric lung disease Year: 2018 Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma Source: Annual Congress 2013 –Asthma Year: 2013